

Daniel Gioeli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8275019/publications.pdf>

Version: 2024-02-01

47
papers

2,962
citations

186265

28
h-index

223800

46
g-index

49
all docs

49
docs citations

49
times ranked

3893
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgen Receptor Phosphorylation. <i>Journal of Biological Chemistry</i> , 2002, 277, 29304-29314.	3.4	299
2	Matrix Rigidity Regulates Cancer Cell Growth and Cellular Phenotype. <i>PLoS ONE</i> , 2010, 5, e12905.	2.5	285
3	Stress Kinase Signaling Regulates Androgen Receptor Phosphorylation, Transcription, and Localization. <i>Molecular Endocrinology</i> , 2006, 20, 503-515.	3.7	163
4	Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. <i>Cancer Research</i> , 2003, 63, 1981-9.	0.9	157
5	FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells. <i>Molecular and Cellular Biology</i> , 2010, 30, 1243-1253.	2.3	152
6	Ras signaling in prostate cancer progression. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 13-25.	2.6	146
7	CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation. <i>Molecular Endocrinology</i> , 2010, 24, 2267-2280.	3.7	119
8	Post-translational modification of the androgen receptor. <i>Molecular and Cellular Endocrinology</i> , 2012, 352, 70-78.	3.2	115
9	Integration of Rapid Signaling Events with Steroid Hormone Receptor Action in Breast and Prostate Cancer. <i>Annual Review of Physiology</i> , 2007, 69, 171-199.	13.1	112
10	Androgen receptor phosphorylation: biological context and functional consequences. <i>Endocrine-Related Cancer</i> , 2014, 21, T131-T145.	3.1	105
11	Signal transduction in prostate cancer progression. <i>Clinical Science</i> , 2005, 108, 293-308.	4.3	103
12	Receptor for Activated C Kinase 1 (RACK1) and Src Regulate the Tyrosine Phosphorylation and Function of the Androgen Receptor. <i>Cancer Research</i> , 2006, 66, 11047-11054.	0.9	103
13	SUMO-Specific Protease 1 (SEN1) Reverses the Hormone-Augmented SUMOylation of Androgen Receptor and Modulates Gene Responses in Prostate Cancer Cells. <i>Molecular Endocrinology</i> , 2009, 23, 292-307.	3.7	93
14	The Androgen Receptor Acetylation Site Regulates cAMP and AKT but Not ERK-induced Activity. <i>Journal of Biological Chemistry</i> , 2004, 279, 29436-29449.	3.4	74
15	Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. <i>Cancer Research</i> , 2003, 63, 1975-80.	0.9	66
16	Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1581-1590.	4.1	63
17	Transient, Ligand-Dependent Arrest of the Androgen Receptor in Subnuclear Foci Alters Phosphorylation and Coactivator Interactions. <i>Molecular Endocrinology</i> , 2004, 18, 834-850.	3.7	62
18	Simian Virus 40 Small t Antigen Mediates Conformation-Dependent Transfer of Protein Phosphatase 2A onto the Androgen Receptor. <i>Molecular and Cellular Biology</i> , 2005, 25, 1298-1308.	2.3	61

#	ARTICLE	IF	CITATIONS
19	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. <i>EBioMedicine</i> , 2016, 10, 85-100.	6.1	56
20	The Neuroendocrine-Derived Peptide Parathyroid Hormone-Related Protein Promotes Prostate Cancer Cell Growth by Stabilizing the Androgen Receptor. <i>Cancer Research</i> , 2009, 69, 7402-7411.	0.9	54
21	Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. <i>Neuro-Oncology</i> , 2018, 20, 192-202.	1.2	52
22	Identification of Kinases Regulating Prostate Cancer Cell Growth Using an RNAi Phenotypic Screen. <i>PLoS ONE</i> , 2012, 7, e38950.	2.5	51
23	Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. <i>Oncotarget</i> , 2013, 4, 622-635.	1.8	44
24	The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, R395-R407.	3.1	34
25	Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2505-2515.	4.1	32
26	α 6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. <i>Cancer Research</i> , 2016, 76, 5163-5174.	0.9	32
27	Subcellular Localization Modulates Activation Function 1 Domain Phosphorylation in the Androgen Receptor. <i>Molecular Endocrinology</i> , 2007, 21, 2071-2084.	3.7	31
28	Cell-cycle-dependent regulation of androgen receptor function. <i>Endocrine-Related Cancer</i> , 2015, 22, 249-264.	3.1	30
29	Activation of the DNA-dependent Protein Kinase Stimulates Nuclear Export of the Androgen Receptor in Vitro. <i>Journal of Biological Chemistry</i> , 2008, 283, 10568-10580.	3.4	26
30	Rap2 regulates androgen sensitivity in human prostate cancer cells. <i>Prostate</i> , 2007, 67, 1590-1599.	2.3	25
31	Preventing the Androgen Receptor N/C Interaction Delays Disease Onset in a Mouse Model of SBMA. <i>Cell Reports</i> , 2015, 13, 2312-2323.	6.4	25
32	Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells. <i>Lab on A Chip</i> , 2019, 19, 1193-1204.	6.0	25
33	A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells. <i>Oncogene</i> , 2021, 40, 1106-1117.	5.9	24
34	Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth. <i>Cancer Research</i> , 2015, 75, 5093-5105.	0.9	20
35	Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. <i>Oncotarget</i> , 2016, 7, 2734-2753.	1.8	19
36	Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. <i>Clinical Cancer Research</i> , 2021, 27, 1305-1315.	7.0	18

#	ARTICLE	IF	CITATIONS
37	The promise of novel androgen receptor antagonists. <i>Cell Cycle</i> , 2010, 9, 440-449.	2.6	13
38	Role of the runtâ€related transcription factor (RUNX) family in prostate cancer. <i>FEBS Journal</i> , 2021, 288, 6112-6126.	4.7	12
39	Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth. <i>Molecular Cancer</i> , 2019, 18, 113.	19.2	10
40	Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. <i>PLoS ONE</i> , 2015, 10, e0138210.	2.5	9
41	PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells. <i>Molecular Cancer Research</i> , 2020, 18, 1392-1401.	3.4	9
42	IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK. <i>Scientific Reports</i> , 2021, 11, 10826.	3.3	9
43	p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks. <i>Cellular Signalling</i> , 2014, 26, 1627-1635.	3.6	8
44	Immunostaining for activated extracellular signal-regulated kinases in cells and tissue. <i>Methods in Enzymology</i> , 2001, 332, 343-353.	1.0	7
45	Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response. <i>Scientific Reports</i> , 2021, 11, 5535.	3.3	4
46	AR phosphorylation and CHK2 kinase activity regulates IR-stabilized ARâ€CHK2 interaction and prostate cancer survival. <i>ELife</i> , 2020, 9, .	6.0	4
47	Signal Transduction by the Rasâ€MAP Kinase Pathway in Prostate Cancer Progression. , 2008, , 223-256.		1